Group 1 - The company expects a significant decline in net profit for the year 2025, projecting a decrease of over 50% compared to the previous year [1][2] - The performance forecast period is from January 1, 2025, to December 31, 2025, with the net profit expected to be positive but substantially lower [1] - The decline in performance is attributed to a sluggish market and intense competition in the taurine market, leading to a decrease in both the sales volume and prices of the main product, taurine [2] Group 2 - The performance forecast has not been audited by the accounting firm, and the final financial data will be confirmed in the annual report for 2025 [1][3] - Initial communication regarding the performance forecast has taken place with the annual audit accounting firm, but specific data will depend on the final audit results [1][3]
潜江永安药业股份有限公司 2025年度业绩预告